Curis, Inc.
Investor Relations Department
4 Maguire Road
Lexington, MA 02421
United States

Visit IR website
Sign-up for email alerts

NASDAQ: CRIS	
Last Trade:	2.78
Trade Time:	4:00 PM ET Mar 30, 2017
Change:	-0.07 (2.456%)
Day Range	2.77 - 2.88
52-Week Range	1.47 - 3.72
Volume	402,875

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. In expanding its drug development efforts in the field of cancer through its proprietary targeted cancer programs, Curis is building upon its previous experiences in targeting signaling pathways for the development of next generation targeted cancer therapies. For more information, visit Curis' website at www.curis.com.... (more)

Stock Performance

Press Releases [View all]

Mar 30, 2017
Curis to Present Preclinical Data on IRAK4 Kinase Inhibitor CA-4948 at AACR Annual Meeting

Mar 16, 2017
Curis to Present at the Oppenheimer & Co. Inc. 27th Annual Healthcare Conference

Mar 9, 2017
Curis Reports Fourth Quarter and Year-End 2016 Financial Results

Mar 7, 2017
Curis to Release Fourth Quarter and Year End 2016 Financial Results and Hold Conference Call on March 9, 2017

Mar 1, 2017
Curis to Present at the Cowen and Company 37th Annual Health Care Conference

Financials [View all]

Fourth Quarter Financial Results

Mar 9, 2017
Annual Report (10-K)

Apr 5, 2016
Proxy Statement (DEF 14A)

Nov 3, 2016
Quarterly Report (10-Q)

Aug 4, 2016
Quarterly Report (10-Q)

May 9, 2016
Quarterly Report (10-Q)